ONC201 plus atezolizumab for endometrial cancer and obesity
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to sign consent forms
- Your cancer must be endometrial cancer that has come back or spread, and doctors must confirm it with biopsy results
- You need at least one visible tumor spot doctors can measure on scans
- Your cancer must have gotten worse after at least one prior treatment for spread, or within 12 months after chemo given to prevent recurrence
- You must be well enough to do daily activities (ECOG 0, 1, or 2) and expected to live at least 3 months
- You must meet blood test and organ function requirements from tests done within 72 hours before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This study tests an experimental drug called OPB-201 for people with certain gynecologic cancers (endometrial, ovarian, peritoneal, or fallopian tube) that have come back after treatment. The drug is designed to help your immune system recognize and fight cancer cells that carry a specific marker called PRAME.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.